Novo Nordisk

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
54,393
Employees54,393
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
54,393
Employees54,393

NVO Key Statistics

Market cap
386.44B
Market cap386.44B
Price-Earnings ratio
43.48
Price-Earnings ratio43.48
Dividend yield
0.80%
Dividend yield0.80%
Average volume
4.46M
Average volume4.46M
High today
$90.93
High today$90.93
Low today
$86.96
Low today$86.96
Open price
$89.60
Open price$89.60
Volume
4.73M
Volume4.73M
52 Week high
$100.88
52 Week high$100.88
52 Week low
$50.45
52 Week low$50.45

NVO News

Benzinga 15h
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner

Novo Nordisk A/S NVO successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Oze...

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Reuters 17h
Novo Nordisk owner sees chance to go public will open within 18 ... - Reuters

COPENHAGEN, Oct 3 (Reuters) - The CEO of Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk (NOVOb.CO), said on Tuesday he sees the window for...

Novo Nordisk owner sees chance to go public will open within 18 ... - Reuters
Fortune 1d
Ozempic and Wegovy ‘significantly’ improve blood sugar and weight for the long-term, new study suggests - Fortune

Semaglutides—weight loss and diabetes injectables like Wegovy, Ozempic, and Rybelsus—significantly improved blood sugar control and weight in adults with type 2...

Ozempic and Wegovy ‘significantly’ improve blood sugar and weight for the long-term, new study suggests - Fortune

Analyst ratings

61%

of 28 ratings
Buy
60.7%
Hold
25%
Sell
14.3%

NVO Earnings

$0.00
$0.21
$0.43
$0.64
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Q2 FY23
Q3 FY23
Estimated
$0.48 per share
Estimated$0.48 per share
Actual
Available Nov 2
ActualAvailable Nov 2

More NVO News

Yahoo Finance 1d
Novo Nordisk Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Novo Nordisk (NVO) closed the most recent trading day at $91.80, moving +0.95% from the previous trading session. This move outpaced the S&P 500's daily gain of...

Novo Nordisk Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Reuters 1d
US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

FILE PHOTO: Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen By Blake Brittain WASHINGTON (Reuters) - A U.S. Pate...

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic
Reuters 1d
Drugmakers sign on to negotiate Medicare prices under protest - Reuters

U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan...

Drugmakers sign on to negotiate Medicare prices under protest - Reuters
Yahoo Finance 2d
US FDA approves Novo Nordisk's therapy for rare genetic condition - Yahoo Finance

Oct 2 (Reuters) - Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affect...

US FDA approves Novo Nordisk's therapy for rare genetic condition - Yahoo Finance
Benzinga 2d
FDA approves Rivfloza™ for children ≥9 years old and adults living ... - Benzinga

PLAINSBORO, N.J., Oct. 2, 2023 /PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran)...

FDA approves Rivfloza™ for children ≥9 years old and adults living ... - Benzinga
Yahoo Finance 2d
Novo Nordisk A/S - share repurchase programme - Yahoo Finance

Novo Nordisk A/S Bagsværd, Denmark, 02 October 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Re...

Novo Nordisk A/S - share repurchase programme - Yahoo Finance
CNBC 4d
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Shares of Structure Therapeutics rose more than 30% on Friday after the biotech startup's experimental obesity pill succeeded in a small early-stage trial. The...

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.